 CAMBRIDGE, Mass., March 18, 2021 GLOBE NEWSWIRE -- Cyclerion Therapeutics, Inc. Nasdaq: CYCN, a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Christopher Wright, M.D., Ph.D., Chief Medical Officer, has resigned his position with the company. He will provide Cyclerion with transitional support until March 26, 2021 and will join the Companys Clinical Advisory Board. 